Cancer targets in the Ras pathway

P. Rodriguez-Viciana, O. Tetsu, K. Oda, J. Okada, Katherine A Rauen, F. McCormick

Research output: Contribution to journalArticle

77 Scopus citations

Abstract

Ras proteins play a direct causal role in human cancer and in other diseases. Mutant H-Ras, N-Ras, and K-Ras occur in varying frequencies in different tumor types, for reasons that are not known. Other members of the Ras superfamily may also contribute to cancer. Mutations also occur in downstream pathways, notably B-Raf, PTEN, and PI 3′ kinase: These pathways interact at multiple points, including cyclin D1, and act synergistically. In some cases mutations in Ras and effectors are mutually exclusive; in other cases, they coexist. Drugs blocking elements of the pathway are in different stages of clinical development. One of these, the Raf kinase/VEGF-R2 inhibitor Sorafenib, has already been approved for treatment of renal cancer and is being tested in other indications. However, therapeutic targets in the Ras pathway have not yet been fully validated as bona fide targets.

Original languageEnglish (US)
Pages (from-to)461-467
Number of pages7
JournalCold Spring Harbor Symposia on Quantitative Biology
Volume70
DOIs
StatePublished - 2005
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Cancer targets in the Ras pathway'. Together they form a unique fingerprint.

  • Cite this

    Rodriguez-Viciana, P., Tetsu, O., Oda, K., Okada, J., Rauen, K. A., & McCormick, F. (2005). Cancer targets in the Ras pathway. Cold Spring Harbor Symposia on Quantitative Biology, 70, 461-467. https://doi.org/10.1101/sqb.2005.70.044